Hikal Ltd.

NSE: HIKAL | BSE: 524735 | ISIN: INE475B01022 | Industry: Pharmaceuticals
| Expensive Star
416.7000 -8.95 (-2.10%)
NSE Apr 04, 2025 11:23 AM
Volume: 429.1K
 

logo
Hikal Ltd.
02 Aug 2019
416.70
-2.10%
ICICI Securities Limited
Q1 revenues grew 23.8% YoY to | 403.2 crore (I-direct estimate: | 368.4 crore) on account of 15.2% YoY growth in pharma segment to | 203.9 crore (I-direct estimate: | 212.4 crore) and 34.1% YoY growth in crop protection segment to | 199.3 crore (I-direct estimate: | 156.1 crore). EBITDA margins contracted 163 bps YoY to 17.0%, (I-direct estimate: 18.5%), fall in gross margins (43.4% vs. 49.4% in Q1FY19) was partly offset by decline in other expenditure. EBITDA grew 13% YoY to | 68.5 crore (I-direct estimate: | 68.1 crore. Net profit grew 58.4% YoY to | 25.2 crore (I-direct estimate of | 18.5...
Hikal Ltd. has gained 44.36% in the last 1 Year
More from Hikal Ltd.
Recommended